132 related articles for article (PubMed ID: 24216602)
1. Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients.
Tarkun P; Birtas Atesoglu E; Mehtap O; Musul MM; Hacihanefioglu A
Acta Haematol; 2014; 131(3):173-8. PubMed ID: 24216602
[TBL] [Abstract][Full Text] [Related]
2. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma.
Kim JE; Yoo C; Lee DH; Kim SW; Lee JS; Suh C
Ann Hematol; 2010 Apr; 89(4):391-7. PubMed ID: 19844712
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
4. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
5. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
6. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
7. Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.
Maillet D; Montiel-Cervantes L; Padilla-González Y; Sánchez-Cortés E; Xolotl-Castillo M; Vela-Ojed J; Reyes-Maldonado E
Rev Invest Clin; 2012; 64(1):17-24. PubMed ID: 22690525
[TBL] [Abstract][Full Text] [Related]
8. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
9. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction.
Izumiya Y; Hanatani S; Kimura Y; Takashio S; Yamamoto E; Kusaka H; Tokitsu T; Rokutanda T; Araki S; Tsujita K; Tanaka T; Yamamuro M; Kojima S; Tayama S; Kaikita K; Hokimoto S; Ogawa H
Can J Cardiol; 2014 Mar; 30(3):338-44. PubMed ID: 24484911
[TBL] [Abstract][Full Text] [Related]
10. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
11. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer.
Staff AC; Bock AJ; Becker C; Kempf T; Wollert KC; Davidson B
Gynecol Oncol; 2010 Sep; 118(3):237-43. PubMed ID: 20576287
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between serum growth differentiation factor-15 and TIMI risk scores in patients with unstable angina pectoris].
Deng MY; Wu GP; Feng XX; Luo JB
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1277-8. PubMed ID: 21764714
[TBL] [Abstract][Full Text] [Related]
14. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
15. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
17. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
19. Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.
Hsiao LT; Yang CF; Yang SH; Gau JP; Yu YB; Hong YC; Liu CY; Liu JH; Chen PM; Chiou TJ; Tzeng CH
Eur J Haematol; 2012 Feb; 88(2):159-66. PubMed ID: 21973045
[TBL] [Abstract][Full Text] [Related]
20. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
Anand IS; Kempf T; Rector TS; Tapken H; Allhoff T; Jantzen F; Kuskowski M; Cohn JN; Drexler H; Wollert KC
Circulation; 2010 Oct; 122(14):1387-95. PubMed ID: 20855664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
